This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Request Permissions Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Moss, R. L. Articles by Periera, J. S.’A. Search for Related Content PubMed PubMed Citation Articles by Moss, R. L. Articles by Periera, J. S.’A. Pubmed/NCBI databases Substance via MeSH Medline Plus Health Information Cardiomyopathy Related Collections Contractile function Animal models of human disease Genetically altered mice Myocardial cardiomyopathy disease

(Circulation Research. 2000;86:720.)
© 2000 American Heart Association, Inc.

Editorial

Enhanced Myosin Function Due to a Point Mutation Causing a Familial Hypertrophic Cardiomyopathy

Richard L. Moss, Jose Sant’Ana Periera

From the Department of Physiology, University of Wisconsin Medical School, Madison, Wis.

Correspondence to Richard L. Moss, PhD, 1300 University Ave, Madison, WI 53706. E-mail rlmoss@physiology.wisc.edu

Key Words: hypertrophic cardiomyopathy • myosin • contraction • kinetics

	Introduction

 
Most cases of familial hypertrophic cardiomyopathy have been attributed to mutations in thick or thin filament proteins in the myofibrils of myocardial cells.^{1 2 3} In a minority of cases, particularly those involving myosin binding protein C, such mutations have been associated with enhanced myofibrillar function, which has been inferred from changes in force and the kinetics of force development and relaxation in isolated muscle preparations and from changes in the dynamics of pressure development in working hearts. In most cases, such as those involving thin filament regulatory proteins or subunits of myosin, familial hypertrophic cardiomyopathy (FHC) mutations have been associated with depressed function in working hearts in living or skinned myocardium or in biochemical and other in vitro assays of actomyosin interaction.³ Whether myofibrillar function is enhanced or depressed, the hearts of affected individuals undergo hypertrophy as an adaptive response to altered myocardial function, and for particularly malignant mutations, there is a significantly increased probability of premature death because of mechanical or electrical abnormalities of the heart.

Although several FHC mutations have been identified using gene mapping approaches, little is known about the effects of most of the mutations on myofibrillar function or integrated contractile function in the context of human intact cardiac myocytes, muscle strips, or working hearts. However, in the case of one of these mutations, R403Q in the human ß-myosin heavy chain (MHC), recent studies^{4 5} have taken advantage of the fact that mammalian slow muscle MHC is identical to cardiac ß-MHC to obtain muscle that was heterozygous for . . . [Full Text of this Article]

This article has been cited by other articles:

				Q. Wang, C. L. Moncman, and D. A. Winkelmann Mutations in the motor domain modulate myosin activity and myofibril organization J. Cell Sci., October 15, 2003; 116(20): 4227 - 4238. [Abstract] [Full Text] [PDF]

				G. Miller, J. Maycock, E. White, M. Peckham, and S. Calaghan Heterologous expression of wild-type and mutant {beta}-cardiac myosin changes the contractile kinetics of cultured mouse myotubes J. Physiol., April 1, 2003; 548(1): 167 - 174. [Abstract] [Full Text] [PDF]